Glioma therapy up-date;Actualización del tratamiento de los gliomas

Neurologia

Volumn 22, Issue 3, 2007, Pages 159-169

  Pilo De La Fuente, B ^a   Dalmau, Josep ^b   Rosenfeld, M ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain tumor; Glioblastoma multiforme; Temozolomide

Indexed keywords

ALKYLATING AGENT; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE;

CANCER SURVIVAL; DNA DAMAGE; DRUG ADSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; PROGNOSIS; REVIEW;

ANTICOAGULANTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CRANIOTOMY; DACARBAZINE; DNA DAMAGE; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FORECASTING; GLIOBLASTOMA; GLIOMA; HUMANS; NEOPLASM PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PALLIATIVE CARE; PROGNOSIS; PROMOTER REGIONS (GENETICS); THROMBOPHILIA;

EID: 34247534879     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999;43:237-9.
2. Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991;48:406-9.
3. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003;63:263-70.
4. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995;52:717-24.
5. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.
6. Husted SE. Principles of thromboprophylaxis in surgical patients. Semin Thromb Hemost 1991;17:254-8.
7. Huisman MV, Nurmohamed M, ten Cate JW. Mechanical prophylaxis of deep vein thrombosis. Semin Thromb Hemost 1991; 17:269-71.
8. Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol 2004;5:511-7.
9. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80-5.
10. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002;122:1933-7.
11. Cingolani A, de Luca A, Larocca LM, Ammassari A, Scerrati M, Antinori A, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 1998;90:364-9.
12. Baumgartner JE, Edwards MS. B. Pineal Tumors. Neurosurg Clin N Am 1992;3:853-62.
13. Burger PC, Scheithauer BW, Lee RR, O'Neill BP. An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions. Cancer 1997;80:2040-6.
14. Barker FG, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936-41.
15. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436-40.
16. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
17. Stupp R, Dietrich PY, Ostermann KS, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
18. Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
19. Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol 1991;36:106-11.
20. Fulton DS, Urtasun RC, Scott-Brown I, Johnson ES, Mielke B, Curry B, et al. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J Neurooncol 1992; 14:63-72.
21. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas-re- evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988;279-84.
22. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990;28:818-22.
23. Archibald YM, Lunn D, Ruttan LA, Macdonald DR, del Maestro RF, Barr HW, et al. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994;80:247-53.
24. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
25. Sneed PK, Gutin PH, Larson DA, Malec MK, Phillips TL, Prados MD, et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994;29:719-27.
26. Leibel SA, Ling CC, Kutcher GJ, Mohan R, Cordon-Cordo C, Fuks Z. The biological basis for conformal three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:805-11.
27. Spirou SV, Chui CS. Generation of arbitrary intensity profiles by dynamic jaws or multileaf collimators. Med Phys 1994;21:1031-41.
28. Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin Oncol 2004;31:702-13.
29. Gutin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, et al. External irradiation followed by an interstitial high activity iodine-125 implant «boost» in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 1991;21:601-6.
30. Chun M, McKeough P, Wu A, Kasdon D, Heros D, Chang H. Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience. Br J Radiol 1989;62:158-62.
31. Roberge D, Souhami L. Stereotactic radiosurgery in the management of intracranial gliomas. Technol Cancer Res Treat 2003; 2:117-25.
32. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
33. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71: 2585-97.
34. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33:9045-51.
35. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-91.
36. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 1998;42: 433-40.
37. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-36.
38. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
39. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-93.
40. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
41. Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004;100:2208-14.
42. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 2002;4:261-7.
43. Van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000;47:779-84.
44. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
45. Gorlia T, Stupp R, Eisenhauer EA, Mirimanoff RO, van den Bent MJ, Belanger K, et al. Clinical Prognostic Factors Affecting Survival in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM). J Clin Oncol 2004;22:9599.
46. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-52.
47. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-8.
48. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
49. Grafstrom RC, Pegg AE, Trump BF, Harris CC. O6-alkylguanine-DNA alkyltransferase activity in normal human tissues and cells. Cancer Res 1984;44:2855-7.
50. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, et al. Correlation of tumor 06 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-5.
51. Schold SC Jr, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, et al. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 1989;70:573-7.
52. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11.
53. Perry J, Rizek P, Morrison T, Cashman R, Haller T. Gliomas respond to low dose temozolomide even after following progression on a conventional 5/28 day schedule. Neurology 2004;62: A543.
54. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5:807-14.
55. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
56. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
57. Esteller M, García-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
58. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
59. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
60. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23: 360-4.
61. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573-4.
62. Van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-8.
63. Van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599-602.
64. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
65. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10.
66. Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 2004;5:295-306.
67. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45.